Overview

Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) Study

Status:
Completed
Trial end date:
2018-10-08
Target enrollment:
Participant gender:
Summary
The present study is designed to determine the effect of valproic acid (VAL), a UGT2B7 inhibiting drug, on the pharmacokinetics (PK) of estetrol (E4)
Phase:
Phase 1
Details
Lead Sponsor:
Estetra
Collaborator:
Quotient Sciences
Treatments:
Drospirenone
Valproic Acid